Robin Sanderson

Honorary Senior Lecturer

King’s College London

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Immunology Immunology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Robin Sanderson is an Honorary Senior Lecturer at King's College London, UK. His research focuses on hematology, particularly CAR T-cell therapies and their socioeconomic impacts on patient outcomes in large B-cell lymphoma. He has contributed to key guidelines and systematic reviews in the diagnosis and management of mantle cell lymphoma, and has investigated the nutritional effects of various therapies on adult patients.

Articles (8)

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (5)

Claire Roddie

University Hospital

UNITED KINGDOM

View details

Andrea Kuhnl

King's College Hospital

UNITED KINGDOM

View details

Piers Patten

King’s College London

UNITED KINGDOM

View details

Kevin Walsh

King’s College London

UNITED KINGDOM

View details

Sanne Lugthart

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Robin Sanderson

Research Interests

Explore related searches

Contact this professor

About

Articles (8)

CAR T access and outcomes in large B‐cell lymphoma according to ethnicity and socioeconomic deprivation in the UK

Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline

Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis

The nutritional impact of CD19‐targeted CAR‐T therapy versus BEAM chemotherapy for adult patients with lymphoma

Chimeric Antigen Receptor T-Cell Therapy and Imaging Applications for Large B-Cell Lymphoma

A national service for delivering CD19 CAR-Tin large B-cell lymphoma – The UK real-world experience

Addendum to British Society for Haematology Guideline for the management of mantle cell lymphoma, 2018 (Br. J. Haematol. 2018; 182: 46-62): Risk assessment of potential CAR T candidates receiving a covalent Bruton tyrosine kinase inhibitor for relapsed/refractory disease.

Severe presentations and high mortality from SARS-CoV-2 in patients undergoing chimeric antigen receptor (CAR-T) therapy: a UK NCCP analysis.

Collaborators (5)

Claire Roddie

Andrea Kuhnl

Piers Patten

Kevin Walsh

Sanne Lugthart

Make your next move.